Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Screener

CARM

Carisma Therapeutics Inc

May 17 • 04:00PM ET

1.41

Dollar change +0.04
Percentage change 2.92	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Revenue • Dividends • Options Options Chain • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWN VTWO IWC BSVO OMFS VTWV FESM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.01	Insider Own	51.90%	Shs Outstand	40.61M	Perf Week	-4.73%
Market Cap	58.57M	Forward P/E	-	EPS next Y	-1.03	Insider Trans	0.00%	Shs Float	19.98M	Perf Month	-17.54%
Income	-81.22M	PEG	-	EPS next Q	-0.30	Inst Own	17.11%	Short Float	9.11%	Perf Quarter	-38.70%
Sales	15.07M	P/S	3.89	EPS this Y	52.05%	Inst Trans	-32.33%	Short Ratio	10.35	Perf Half Y	-44.92%
Book/sh	0.26	P/B	5.38	EPS next Y	16.91%	ROA	-70.64%	Short Interest	1.82M	Perf Year	-71.05%
Cash/sh	1.36	P/C	1.04	EPS next 5Y	-	ROE	-167.51%	52W Range	1.35 - 9.77	Perf YTD	-51.88%
Dividend Est.	-	P/FCF	-	EPS past 5Y	24.98%	ROI	-559.22%	52W High	-85.56%	Beta	1.40
Dividend TTM	-	Quick Ratio	4.64	Sales past 5Y	25.00%	Gross Margin	65.59%	52W Low	4.83%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	4.64	EPS Y/Y TTM	47.72%	Oper. Margin	-565.71%	RSI (14)	30.64	Volatility	6.31% 6.91%
Employees	107	Debt/Eq	0.69	Sales Y/Y TTM	-65.14%	Profit Margin	-538.81%	Recom	1.40	Target Price	7.60
Option/Short	No / Yes	LT Debt/Eq	0.33	EPS Q/Q	75.95%	Payout	-	Rel Volume	1.27	Prev Close	1.37
Sales Surprise	-22.71%	EPS Surprise	-6.36%	Sales Q/Q	4.75%	Earnings	May 09 BMO	Avg Volume	175.85K	Price	1.41
SMA20	-11.06%	SMA50	-26.98%	SMA200	-54.76%	Trades		Volume	223,335	Change	2.92%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-11-24	Initiated	BTIG Research	Buy	$6
Oct-03-23	Initiated	CapitalOne	Overweight	$10
Jul-06-23	Initiated	Evercore ISI	Outperform	$12
May-31-23	Upgrade	Jefferies	Hold → Buy	$0.60 → $7
May-24-23	Initiated	H.C. Wainwright	Buy	$10
Apr-14-23	Initiated	Robert W. Baird	Outperform	$10

May-16-24 07:30AM	Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte (PR Newswire)
May-09-24 01:54PM	CARM Stock Earnings: CARISMA Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:35AM	Carisma Therapeutics Inc. (CARM) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (PR Newswire)
May-08-24 07:30AM	Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 (PR Newswire)
07:30AM	Loading…
May-06-24 07:30AM	Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference (PR Newswire)
May-02-24 10:01AM	Carisma Therapeutics Inc. (CARM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
07:30AM	Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer (PR Newswire)
Apr-24-24 05:05PM	Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting (PR Newswire)
Apr-22-24 04:35PM	Carisma Therapeutics to Present New Data at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (PR Newswire) +14.72%
Apr-04-24 09:55AM	Here's Why CARISMA THERAP (CARM) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Apr-03-24 07:00AM	Carisma Therapeutics to Present at Upcoming Conferences (PR Newswire)
Apr-01-24 01:53PM	CARM Stock Earnings: CARISMA Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) -7.93%
08:35AM	Carisma Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
07:00AM	Carisma Therapeutics Announces Changes to its Board of Directors (PR Newswire)
05:00PM	Loading…
Mar-21-24 05:00PM	Carisma Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Feb-28-24 07:30AM	Carisma Therapeutics to Participate in TD Cowen's 44th Annual Health Care Conference (PR Newswire)
Dec-21-23 07:00AM	Carisma Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-14-23 07:00AM	First In Vivo CAR-M Lead Candidate Nominated Under Carisma-Moderna Collaboration (PR Newswire)
Nov-28-23 07:00AM	Carisma Therapeutics Announces FDA Clearance of IND Application for CT-0525, a Novel HER2-Targeting CAR-Monocyte (PR Newswire)
Nov-22-23 07:30AM	Carisma Therapeutics to Participate in Evercore ISI HealthCONx Conference (PR Newswire) +5.74%
Nov-09-23 07:30AM	Carisma Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire) -11.24%
Oct-31-23 09:25AM	Carisma Presents Pre-Clinical Proof of Concept for in vivo CAR-M using mRNA platform in collaboration with Moderna at SITC (PR Newswire)
Oct-25-23 09:11AM	Carisma to Present First Results From in vivo CAR-M Collaboration with Moderna at SITC 2023 (PR Newswire)
Oct-12-23 02:52PM	3 Top Under-$5 Stocks for Strong Gains and Positive Outlook (InvestorPlace) -19.51%
Sep-05-23 08:30AM	Carisma Therapeutics to Present at Upcoming Investor Conferences (PR Newswire) -14.33%
Sep-01-23 08:30AM	Carisma Announces Latest Data from Phase 1 Clinical Trial of CT-0508 at 8th Annual CAR-TCR Summit (PR Newswire) -10.26%
Aug-24-23 08:30AM	Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in September 2023 (PR Newswire)
Aug-23-23 09:55AM	Wall Street Analysts Predict a 48.37% Upside in Carisma Therapeutics Inc. (CARM): Here's What You Should Know (Zacks)
Aug-13-23 08:07AM	Carisma Therapeutics Second Quarter 2023 Earnings: Beats Expectations (Simply Wall St.)
07:30AM	Loading…
Aug-10-23 07:30AM	Carisma Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (PR Newswire) +6.08%
Jul-19-23 06:34AM	Public companies own 19% of Carisma Therapeutics, Inc. (NASDAQ:CARM) shares but retail investors control 43% of the company (Simply Wall St.)
Jun-28-23 08:30AM	Carisma Therapeutics Announces First Patient Dosed in Phase 1 Study of CT-0508 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HER2 Overexpressing Solid Tumors (PR Newswire)
Jun-26-23 08:30AM	Carisma Therapeutics to be Added to Russell 2000®, Russell 3000® and Russell Microcap® Indexes (PR Newswire) -5.24%
Jun-14-23 08:30AM	Carisma Therapeutics Appoints Eric Siegel as General Counsel and Corporate Secretary and Terry Shields as Senior Vice President of Human Resources (PR Newswire)
Jun-08-23 01:11PM	Carisma Therapeutics (NASDAQ:CARM) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jun-05-23 07:30AM	Carisma Therapeutics to Present at Upcoming Investor Conferences in June 2023 (PR Newswire)
May-30-23 04:30PM	Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in June 2023 (PR Newswire)
May-11-23 07:30AM	Carisma Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights (PR Newswire)
May-08-23 04:30PM	Carisma Therapeutics to Present at the JMP Securities Life Sciences Conference (PR Newswire) +9.57%
May-05-23 04:30PM	Carisma Therapeutics to Present at Upcoming Healthcare Industry Conferences in May 2023 (PR Newswire) +8.63%
Apr-14-23 12:51PM	Carisma Therapeutics to Present at The American Association for Cancer Research Annual Meeting (PR Newswire) +14.84%
Apr-06-23 04:30PM	Carisma Therapeutics to Present at Upcoming Healthcare Industry and Investor Conferences in April 2023 (PR Newswire)
Apr-04-23 08:30AM	Carisma Therapeutics Reports Fiscal 2022 Financial Results and Recent Business Highlights (PR Newswire)
Mar-20-23 02:04PM	Carisma Therapeutics CEO Steven Kelly talks reverse merger, growth plans (American City Business Journals) -5.77%

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.

CARM

Carisma Therapeutics Inc

Upgrade your FINVIZ experience